The side effects and mitigation methods of Tazemetostat in the Laotian version of Lucius
Tazemetostat, as an EZH2 methyltransferase inhibitor, commonly has side effects involving hematological toxicity, gastrointestinal reactions, and special population risks, which need to be controlled through laboratory monitoring and symptom management. The following system elaborates on its adverse reaction spectrum and response strategies, including dose adjustment principles and key preventive measures.
1. Abnormal blood system
(1) Anemia: The incidence rate is 46%. When Hb<80g/L, medication should be suspended, and red blood cells should be infused if necessary. It is recommended to monitor the whole blood cell count weekly.
(2) Thrombocytopenia: incidence rate of 35%, avoid using sharp instruments. Immediately check platelet count when experiencing nosebleeds or gum bleeding.
2. Gastrointestinal reactions
(1) Nausea and vomiting: incidence rate of 65%, prophylactic use of 5-HT3 receptor antagonists. Administer 8mg intravenous injection of ondansetron when experiencing grade 2 symptoms (reduced food intake).
(2) Diarrhea: The incidence rate is 51%, and treatment with loperamide is initiated as soon as the number of first bowel movements increases. Maintain water electrolyte balance.
3. Systemic response
(1) Fatigue: incidence rate of 54%, it is recommended to implement a graded activity plan. After excluding thyroid dysfunction, consider adjusting the dosage.
(2) Fever: The incidence rate is 28%, and the source of infection needs to be immediately investigated. When neutropenia is accompanied by fever, broad-spectrum antibiotics should be used.
4. Special risk control
(1) Secondary malignant tumors: Whole blood cytogenetic analysis is conducted every 6 months during treatment. Permanently discontinue medication when symptoms of MDS/AML appear.
(2) Embryotoxicity: Patients of childbearing age should adopt dual contraception measures during treatment and 6 months after discontinuation of medication.
5. Laboratory monitoring requirements
(1) Liver function: Suspend medication when ALT/AST is greater than 3 times the upper limit, and permanently discontinue medication when ALT/AST is greater than 5 times the upper limit. Elevated bilirubin levels require differentiation of hemolytic factors.
(2) Coagulation function: Evaluate bleeding risk when INR>1.5. Avoid co administration with warfarin and prefer low molecular weight heparin.
Disclaimer：《The side effects and mitigation methods of Tazemetostat in the Laotian version of Lucius》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！